Novartis AG (NVS)
NYSE • Healthcare
April 2, 2026 at 20:00 UTC
About Novartis AG
Novartis AG is a pharmaceutical company that discovers, develops, and supplies medicines for conditions managed in specialty and primary care. Its model connects research with manufacturing and patient access so new therapies move from trials to practice under consistent standards. Programs focus on areas where evidence, careful dosing, and long follow-up matter, which is why labeling clarity and clinician education sit alongside science as core work. Supply chains and quality systems are organized for continuity rather than spectacle, keeping availability steady once treatment becomes part of care. Country teams adapt to local frameworks while holding to shared safety principles. Within the healthcare sector, Novartis acts as a long-horizon manufacturer and science organization, turning complex research into options that clinicians can use predictably in hospitals and clinics around the world.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Novartis AG's Technical Indicators Summary
Novartis presents a neutral technical stance where price is above shorter-term moving averages and well above longer-term levels, yet momentum and trend indicators are mixed. RSI and MACD sit near neutral, while ADX suggests a modest trend that has not decisively favored either side. Volatility is subdued and on-balance volume is not providing clear support, and the pivot sits slightly above the market. Technical takeaway: Neutral — mixed momentum and moderate trend strength keep the technical outlook balanced.
| Indicator | Value |
|---|---|
RSI (14) | 50.46 |
Stochastic %K (14, 3, 3) | 80.53 |
CCI (20) | 19.42 |
WPR (14) | -19.02 |
Momentum (10) | 5.84 |
MFI | 51.11 |
MACD Level (12, 26) | -1.49 |
Bollinger Bands | $143.63 - $162.30 |
ATR (14) | $2.99 (1.94%) |
ADX (14) | 28.13 |
OBV | 28,247,800 |
Classic Pivot Point | $155.09 |
Fibonacci Pivot Point | $155.09 |
Simple Moving Averages | $134.57 - $156.20(5 indicators) |
Exponential Moving Averages | $136.35 - $153.28(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
By the close, NVS continued to sit slightly below yesterday’s 155.08, with a small -0.68% gap down and a finish near 154.03. Into the bell, NVS was moving toward an earnings checkpoint, now 25 days out on 28 April. NVS trades modestly lower as investors await its upcoming earnings checkpoint.
Price Change
from $153.99 close
+$0
Trading Volume
Above avg 1.8M
2.5M
vs S&P 500 Today
Underperforming Market
-1.16%
52-Week Position
Upper range
77.4%
Updated: April 3, 2026 at 20:09 UTC
Quote Summary
NVS Headlines
Azoria ETFs shut, Novartis India stake sold, tariff shock
February 20, 2026
Live Nation, PTC, AES Lead Busy Earnings and Energy News
February 19, 2026
Avidity sets spin-off record date pre‑Novartis deal
February 3, 2026
How Recent Rallies Stack Up Against Valuations
January 11, 2026